Abstract
Gilead Sciences and Merck & Co. will collaborate to develop a long-acting HIV treatment that combines Gilead’s capsid inhibitor lenacapavir with Merck’s islatravir, a nucleoside reverse transcriptase translocation inhibitor. The molecules are being studied separately in late-stage trials to treat or prevent HIV. Both have long half-lives and robust virus-suppressing activity at low doses. The goal is to replace the daily regimen of pills taken by people with HIV with one pill that is taken every few months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
